Tiziana Life Sciences Ltd. Common Shares - TLSA STOCK NEWS

Tiziana Life Sciences (NASDAQ: TLSA) reported a 80% qualitative improvement in PET imaging for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients receiving intranasal foralumab for at least six months. The FDA has permitted the enrollment of an additional 20 patients in the Expanded Access Program (EA), aiming to gather more data and analyze for further insights. The company also applied for FDA Orphan Drug Designation for foralumab to treat na-SPMS. This development is a significant milestone for Tiziana's immunomodulation therapies, as stated by Gabriele Cerrone, the acting CEO and founder.

Tiziana Life Sciences (Nasdaq: TLSA), a biotechnology company, has applied for a grant from the ALS Association to fund a clinical trial for intranasal foralumab, an anti-CD3 monoclonal antibody. The grant is part of the Hoffman ALS Clinical Trial Awards Program. The trial aims to evaluate the safety, dosing, and biomarkers of foralumab in ALS patients using cutting-edge imaging techniques like PET scans. Previously, foralumab showed promising results in an Expanded Access Program for non-active secondary progressive multiple sclerosis. The company hopes the grant will support a 6-month trial involving 20 participants, advancing their efforts to develop effective ALS treatments.

Tiziana Life Sciences announced that Dr. Howard L. Weiner, its Scientific Advisory Board Chairman, will receive the 'Giants of MS' award for his contributions to multiple sclerosis (MS) research.

The award will be presented at the Consortium of Multiple Sclerosis Centers annual meeting on May 30, 2024.

Dr. Weiner is celebrated for his work on innovative treatments like intranasal foralumab, which shows promise in improving the lives of MS patients.

Foralumab has shown positive results in an Expanded Access Program, with 70% of patients experiencing improved fatigue.

The drug is also undergoing a Phase 2a trial, with data expected in 2025.

Tiziana Life Sciences, a biotechnology company, files for Orphan Drug Designation for intranasal foralumab for treating non-active secondary progressive Multiple Sclerosis, aiming to be the first therapy to receive this designation. Supported by clinical evidence, the drug has shown positive results in an Expanded Access Program, improving fatigue in 70% of patients. A Phase 2a trial is ongoing, with a data readout expected in 2025. Orphan Drug Designation brings significant benefits if approved.

Tiziana Life Sciences reports positive 3-month neuroimaging scores in multiple sclerosis patients receiving intranasal foralumab. The company announced quantitative data showing improvement in White Matter Z-scores in patients with non-active secondary progressive multiple sclerosis. Dr. Tarun Singhal presented data demonstrating a reduction in microglial activation, indicating a positive effect on brain inflammation. A peer-reviewed journal has published the research findings. Tiziana is currently conducting a double-blind, placebo-controlled study to further evaluate intranasal foralumab's impact.

Tiziana Life Sciences announces FDA allowance for additional patients in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program, with positive clinical data showing improvements in patients' conditions without serious side effects.

Tiziana Life Sciences announced additional positive clinical results from its Expanded Access Program for non-active secondary progressive multiple sclerosis patients, with 70% showing improvement in fatigue after six months of follow-up. All patients stabilized or improved on nasal foralumab treatment. The findings highlight the potential of Tiziana's therapy to address the critical unmet need for individuals living with MS.

Tiziana Life Sciences announced study results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA highlighted in Neurology Today®. The study shows that foralumab attenuates microglial activation in non-active secondary progressive multiple sclerosis patients with progression independent of relapse. The positive results suggest potential benefits for patients with this difficult-to-treat form of MS. The study, presented at the Annual Meeting of the American Academy of Neurology, demonstrates the effect of intranasal foralumab on microglial activation in na-SPMS patients using PET imaging. This breakthrough therapy has the potential to address the unmet need for disease-modifying treatments in progressive MS patients.

Tiziana Life Sciences presents new quantitative PET imaging data on Foralumab at the American Academy of Neurology meeting. The study shows that intranasal Foralumab attenuates microglial activation and stabilizes disease progression in non-active secondary progressive MS patients with PIRA. The presentation includes encouraging imaging data from the Expanded Access Program, demonstrating the effectiveness of Foralumab in treating MS patients. The study highlights the significant impact of Foralumab in addressing the unmet need for effective treatments in progressive MS patients with PIRA.